Peter Voorhees, MD on the Progress Made in 2020 For Patients With Multiple Myeloma

EP: 1.Study Results Show Promise for Neoantigen Targeting Strategies Such as Peptide Vaccines

EP: 2.Recommendations for Under-Representation of African Americans in Multiple Myeloma

EP: 3.Network Meta-Analysis of Treatment Regimens for Relapsed/Refractory Multiple Myeloma

EP: 4.Genetic Patterns Could Help Doctors Identify Ultra High Risk Patients of Multiple Myeloma

Now Viewing

EP: 5.Peter Voorhees, MD on the Progress Made in 2020 For Patients With Multiple Myeloma

EP: 6.Guido Lancman, MD, Discusses Promising Multiple Myeloma Treatments

EP: 7.Lisa La on Areas of Interest Within Multiple Myeloma

EP: 8.Guido Lancman, MD, on Areas of Focus for Multiple Myeloma

EP: 9.Lisa La on Up-and-Coming Multiple Myeloma Research

EP: 10.Deepu Madduri, MD, on Research in Multiple Myeloma This Past Year

Two new FDA approvals for patients with multiple myeloma – isatuximab (Sarclisa) and daratumumab (Darzalex) – were practice changing for 2020, according to Peter Voorhees, MD, of the Levine Cancer Institute.

In an interview with CancerNetwork, Voorhees noted that despite the many challenges that arose in 2020, immense progress was made for patients with multiple myeloma, both in the frontline and relapsed/refractory setting.

Transcription:

I would say that in spite of the [coronavirus disease 2019 (COVID-19)] pandemic, there's been tremendous progress in the field of multiple myeloma.

I think the addition of the CD38 monoclonal antibodies into frontline therapy and newly diagnosed myeloma patients has changed practice. I think that the immunotherapies that are being developed in relapsed and refractory multiple myeloma patients are highly promising and continue to show significant activity in patients who have triple-class refractory disease. The studies are ongoing, many of them will be presented at this year's ASH, so in spite of very trying circumstances, we continue to make considerable progress against this disease.